FDA keeps US breast implant business from competition
This article was originally published in Clinica
The reason the [breast implant] market is the way it is, is the high cost of entry. It is simple. It's three letters- F- D- A-," Inamed's president and co-CEO, Ilan Reich, told the conference. He asserted that the heavy US regulation and the niche nature of the business insulates it from new entrants.